[1] Keshavarzian A,Farhadi A,Forsyth CB,et al. Evidence that chronic alcohol exposure promotes intestinal oxidative stress,intestinal hyperpermeability and endotoxemia prior to development of alcoholic steatohepatitis in rats. J Hepatol,2009,50(3):538-547. [2] Abenavoli L,Masarone M,Persico M. et al. Alcoholic hepatitis:Pathogenesis,diagnosis and treatment. Rev Recent Clin Trials,2016,11(3):159-166. [3] Hayashi N,Saito T,Tsutsumi M,et al. Pathogenesis of alcoholic chronic hepatitis. Nihon Arukoru Yakubutsu Igakkai Zasshi,2014,49(5):219-226. [4] Han SH,Suk KT,Kim EJ,et al. Effects of probiotics (cultured Lactobacillus subtilis/Streptococcus faecium) in the treatment ofalcoholic hepatitis:randomized-controlled multicenter study. Eur J Gastroenterol Hepatol,2015,27(11):1300-1306. [5] Bluemel S,Williams B,Schnabl B,et al. Precision medicine in alcoholic and nonalcoholic fatty liver disease via modulating the gut microbiota. Am J Physiol Gastrointest Liver Physiol,2016,311(6):G1018-G1036. [6] Sung H,Kim SW,Suk KT,et al. Microbiota-based treatments in alcoholic liver disease. World J Gastroenterol,2016,22(29):6673-6682. [7] Groschwitz KR,Hogan SP. Intestinal barrier function:molecular regulation and disease pathogenesis. J Allergy Clin Immunol,2009,124(1):3-20. [8] Fukata M,Abreu MT. TLR4 signalling in the intestine in health and disease. Biochem Soc Trans,2007,35(Pt 6):1473-1478. [9] Neal MD,Sodhi CP,Hackam DJ. A critical role for TLR4 induction of autophagy in the regulation of enterocyte migration and the pathogenesis of necrotizing enterocolitis. J Immunol,2013,190(7):3541-3551. [10] 荆科,孙梅. 肠三叶因子对内毒素血症幼鼠肠组织Toll样受体2和4表达的影响. 中国当代儿科杂志,2011,13(12):985-988. [11] Li X,Chen W,Xu YQ,et al. Toll-like receptor 4 increases intestinal permeability through up-regulation of membrane PKC activity in alcoholic steatohepatitis. Alcohol,2013,47(6):459-465. [12] 李鑫,王晨,徐有青,等. Toll样受体4参与了酒精性肝病肠道高通透性.中华肝脏病杂志,2014,22(2):61-64. [13] Wang K,Feng X,Qiu F,et al. The metabolism of berberine and its contribution to the pharmacological effects. Drug Metab Rev,2017,14:1-54. [14] Li M,Zhang M,Liao CX,et al. Induction of apoptosis by berberine in hepatocellular carcinoma HepG2 cells via downregulation of NF-κB. Oncol Res,2017,25(2):233-239. [15] Yan F,Wang LH,Polk DB,et al. Berberine promotes recovery of colitis and inhibits inflammatory responses in colonic macrophages and epithelial cells in DSS-treated mice. Am J Physiol Gastrointest Liver Physiol,2012,302(5):G504-G514. [16] Li GH,Zhang YP,Tang JL,et al. Effects of berberine against radiation-induced intestinal injury in mice. Int J Radiat Oncol Biol Phys,2010,77(5):1536-1544. [17] Watanabe Y,Yamamoto M,Watanabe K,et al. Orengedokuto and berberine improve indomethacin-induced small intestinal injury via adenosine. J Gastroenterol,2009,44(5):380-389. [18] Chu M,Ding R,Wang YD,et al. Role of berberine in anti-bacterial as a high-affinity LPS antagonist binding to TLR4/MD-2 receptor. BMC Complement Altern Med,2014,14:89. [19] Li HM,Wang YY,Wang HD,et al. Berberine protects against lipopolysaccharide-induced intestinal injury in mice via alpha 2 adrenoceptor independent mechanisms. Acta Pharmacol Sin,2011,32(11):1364-1372. [20] Gong J,Hu M,Lu F,et al. Berberine attenuates intestinal mucosal barrier dysfunction in type 2 diabetic rats. Front Pharmacol,2017,3(8):42. |